Diagnosis Index entries containing back-references to I73.00: Asphyxia, asphyxiation (by) R09.01 ICD-10-CM Diagnosis Code R09.01 Phenomenon Raynaud's (secondary) I73.00 Raynaud's disease, phenomenon or syndrome (secondary) I73.00 Syndrome - see also Disease Raynaud's I73.00
I73.00 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM I73.00 became effective on October 1, 2018. This is the American ICD-10-CM version of I73.00 - other international versions of ICD-10 I73.00 may differ.
Named after French physician Maurice Raynaud (1834–1881), the phenomenon is believed to be the result of vasospasms that decrease blood supply to the respective regions. Inclusion Terms are a list of concepts for which a specific code is used.
When looking at combinations of the VEDOSS criteria, patients with Raynaud's phenomenon who have ANA, systemic sclerosis-specific autoantibodies, and puffy fingers at baseline represented the highest proportion of progressors (16 [94·1%] of 17).
Z86. 79 Personal history of other diseases of the circulatory system - ICD-10-CM Diagnosis Codes.
Z87. 09 - Personal history of other diseases of the respiratory system | ICD-10-CM.
69 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z86. 69 became effective on October 1, 2021. This is the American ICD-10-CM version of Z86.
M32. 10 Systemic lupus erythematosus, organ or system...
9: Fever, unspecified.
ICD-10-CM Code for Personal history of diseases of the respiratory system Z87. 0.
Do not code conditions that were previously treated and no longer exist. However, history codes (categories Z80-Z87) may be used as secondary codes if the historical condition or family history has an impact on current care or influences treatment.
The following questions and answers were jointly developed and approved by the American Hospital Association's Central Office on ICD-10-CM/PCS and the American Health Information Management Association. ICD-10-CM code U07. 1, COVID-19, may be used for discharges/date of service on or after April 1, 2020.
History Code Guidelines Personal history codes may be used in conjunction with follow-up codes and family history codes may be used in conjunction with screening codes to explain the need for a test or procedure. History codes are also acceptable on any medical record regardless of the reason for visit.
ICD-9 Code Transition: 780.79 Code R53. 83 is the diagnosis code used for Other Fatigue. It is a condition marked by drowsiness and an unusual lack of energy and mental alertness. It can be caused by many things, including illness, injury, or drugs.
9: Systemic lupus erythematosus, unspecified.
The majority of lupus cases that develop are what is called sporadic, however—that is, no known relative has the disease. Although when lupus develops in people with no family history of lupus, there are likely to be other autoimmune diseases in some family members.
Safety glasses and goggles that have passed impact testing required by ANSI Standard Z87. 1 are stamped “Z87.” Make sure your eye protection has this marking! “Z87+” indicates that the eyewear is even more protective, having passed more stringent high-velocity impact testing.
The Z87. 1 portion of ANSI standards references the standards for Occupational and Educational Personal Eye and Face Protection Devices. These standards help ensure that personal eye and face protection devices provide the necessary protection from impact, non-ionizing radiation, and liquid splash exposures.
Z87 impact testing The first marking you'll likely see on your eyewear is “Z87” or “Z87+”. This is the ANSI standard for impact which helps ensure safety eyewear provides workers with the needed protection from impact hazards. For safety eyewear to pass the basic Z87 standard, it must pass the ball drop test.
Z87+ For work where there is, or may be, impact hazards your safety glasses must be stamped with a Z87+ marking. The Z87+ marking symbolizes that the glasses are Z87. 1 compliant and pass the remaining 3 tests.
Cold weather and stress can trigger attacks. Often the cause of raynaud's is not known. People in colder climates are more likely to develop raynaud's than people in warmer areas. Treatment for raynaud's may include drugs to keep the blood vessels open. There are also simple things you can do yourself, such as.
The 2022 edition of ICD-10-CM I73.0 became effective on October 1, 2021.
In medicine, Raynaud's disease or Raynaud's phenomenon (pronunciation: /reɪˈnoʊz/ ray-NOHZ) is excessively reduced blood flow in response to cold or emotional stress, causing discoloration of the fingers, toes, and occasionally other areas. This condition may also cause nails to become brittle with longitudinal ridges.
Inclusion Terms are a list of concepts for which a specific code is used. The list of Inclusion Terms is useful for determining the correct code in some cases, but the list is not necessarily exhaustive.
The ICD-10-CM Alphabetical Index links the below-listed medical terms to the ICD code I73.0. Click on any term below to browse the alphabetical index.
I73.00 is a billable ICD code used to specify a diagnosis of raynaud's syndrome without gangrene. A 'billable code' is detailed enough to be used to specify a medical diagnosis.
In medicine, Raynaud's disease or Raynaud's phenomenon (pronunciation: /reɪˈnoʊz/ ray-NOHZ) is excessively reduced blood flow in response to cold or emotional stress, causing discoloration of the fingers, toes, and occasionally other areas. This condition may also cause nails to become brittle with longitudinal ridges.
The ICD10 code for the diagnosis "Raynaud's syndrome without gangrene" is "I73.00". I73.00 is a VALID/BILLABLE ICD10 code, i.e it is valid for submission for HIPAA-covered transactions.
The 2019 edition of ICD-10-CM I73.00 became effective on October 1, 2018.
Preliminary criteria for the very early diagnosis of systemic sclerosis (VEDOSS) have been previously proposed to identify signs and symptoms in patients with Raynaud's phenomenon.
Systemic sclerosis is an autoimmune disease characterised by high clinical heterogeneity in morbidity and mortality.
The VEDOSS project was a multicentre, longitudinal registry study done in 42 EUSTAR centres located in 20 countries in Europe, North America, and South America. Patient enrolment was opened on March 1, 2010.
Between March 1, 2010, and Oct 4, 2018, we included 1150 patients with Raynaud's phenomenon in the VEDOSS database on the basis of available baseline data. 764 (66·4%) of 1150 patients fulfilled the VEDOSS criteria (ie, ANA positive, puffy fingers, systemic sclerosis-specific autoantibody positive, abnormal nailfold capillaroscopy).
This analysis has allowed us to evaluate the clinical, laboratory, and imaging features of patients with Raynaud's phenomenon in a large, prospective, multicentre cohort.
A data dictionary will be made available upon request. Deidentified individual participant data could be made available upon a clinical project request following the standard operating procedures of the World Scleroderma Foundation–European Scleroderma Trial and Research).
LC has had consultancy relationships with Boehringer Ingelheim, Actelion, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Lilly.
Rationale: Scar contractures due to burn injury are reported with code L90.5 that is the first-listed or principal diagnosis and the burn injury is reported as a secondary code to identify the cause of the sequela.
The ‘S’ is added only to the injury code, not the sequela code. The seventh character ‘S’ identifies the injury responsible for the sequela. The specific type of sequela (e.g. scar) is sequenced first, followed by the injury code.”.
The sequela code may also be expanded at the fourth, fifth, or sixth character levels to include the manifestation
Systemic sclerosis (SSc) is a rare disease with studies limited by small sample sizes. Electronic health records (EHRs) represent a powerful tool to study patients with rare diseases such as SSc, but validated methods are needed.
Systemic sclerosis (SSc) is a rare, chronic, autoimmune disease with high morbidity and mortality. Due to its rarity, SSc studies are limited by sample size, with most being single center cohort studies, making it difficult to assess outcomes and comorbidities.
Following approval from the Vanderbilt University Medical Center (VUMC) Institutional Review Board, we analyzed data from a de-identified version of Vanderbilt’s EHR called the Synthetic Derivative [ 1 ].
An outline of our approach is shown in Fig. 1. Within the Synthetic Derivative, we identified 1899 possible SSc cases with at least 1 SSc ICD-9 or ICD-10-CM code.
We developed and validated EHR-based algorithms with high PPVs that combined billing codes with clinical data to identify SSc patients. To the best of our knowledge, we are the first to develop and validate algorithms that combine billing codes with clinical data to identify SSc patients within the EHR.
Accurately identifying SSc patients in the EHR enables researchers to assemble a large and diverse cohort of SSc patients with decreased cost and increased efficiency compared to traditional cohort studies.
The data used and analyzed during the current study are available from the corresponding author on reasonable request. Note that row level data is access controlled and cannot be provided publicly due to data use restrictions.